Duration of response, OS, and FFS. (A) Cumulative incidence curve of duration of response. (B) Kaplan-Meier plot of OS. (C) FFS. Full analysis set, responders only. (A) Duration of response only includes patients whose overall response is CR or PR; the start date is the date of the first documented response of CR or PR, which could be before or at day 28. For duration of response analysis an event was defined as the progression of aGVHD or the addition of systemic therapies for aGVHD after day 28; the competing risks include death without prior observation of aGVHD progression and onset of cGVHD was censored at the last response assessment before or at the analysis cutoff date if no events or competing risks occurred on or before 4 weeks after the last response assessment. (B) OS was defined as the time from the date of the start of study treatment to the date of death from any cause; data were censored at the latest date that the patient was known to be alive. (C) FFS events include hematologic disease relapse/progression, NRM, or the addition of new systemic aGVHD treatment; the competing risk was the onset of cGVHD. Median and quartiles are provided using the Kaplan-Meier method. NE, not estimable.